Skip to main content

Table 3 Predictors of HBV-DNA viremia among patients with HIV-HBV co-infection: Univariate analyses

From: Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil

 

Plasma HBV

DNA < 60 UI/mL

Plasma HBV

DNA > 60 UI/mL

OR

95% CI

p

Sex

    

0. 79

female

2 (66. 67%)

1(33. 33%)

1. 00

  

male

48(59. 26%)

33(40. 74%)

1. 37

0. 11-15. 79

 

Age

    

0. 41

< = 42

22(55%)

18(45%)

1. 00

  

> 42

27(62. 79%)

16(37. 21%)

0. 72

0. 30-1. 74

 

CD4

    

0. 47

< 350 cels/μ1

14 (53. 85%)

12(46. 15%)

1. 00

  

> 350 cels/μ1

36 (62. 07%)

22 (37. 93%)

0. 71

0. 27-1. 81

 

Under HAART*

    

0. 005

yes

50(63. 29%)

29(36. 71%)

   

no

zero

05 (100%)

   

HBV Genotype

     

A

4 (20%)

16 (80%)

0. 36

0-2. 9

0. 63

Non-A

1 (8. 3%)

11 (91. 6%)

1. 00

  

Previous exposure to LAM

    

0. 10

no

2(28. 57%)

5(71. 43%)

1. 00

  

yes

48(62. 34%)

29(37. 66%)

0. 24

0. 04-1. 32

 

Under TDF

    

0. 005

no

15(17. 8%)

21(25. 16%)

1. 00

  

yes

35(41. 6%)

13(15. 4%)

0. 26

0. 10-0. 66

 

Use of TDF > 12 months

    

0. 047

no

21(25%)

27(32. 1%)

1. 00

  

yes

29(34. 5%)

7(8. 2%)

0. 24

0. 059-0. 97

 

ALT level

    

0. 004

Normal

44(53. 6%)

19(23. 1%)

1. 00

  

> 1. 5 ULN**

6(7. 3%)

13(15. 7%)

5. 01

1. 65-15. 17

 

Compliance with therapy

    

0. 033

no

01(14. 29%)

06(85. 71%)

10. 5

1. 20-91. 71

 

yes

49(63. 64%)

28(36. 36%)

1. 00

  
  1. Under HAART*- Previous use of either lamivudine (LAM) or tenofovir (TDF)
  2. ULN**-Upper Limit of Normality